ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1268

Risk Factors for Bone Loss in Juvenile-Onset Systemic Lupus Erythematosus: A Prospective Study

Luiz A Sousa1, Juliane Paupitz1, Nadia E Aikawa2, Liliam Takayama1, Valéria F. Caparbo1 and Rosa M R Pereira3, 1Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers, bone metabolism, dual energy x-ray absorptiometry (DEXA) and juvenile SLE, HR-pQCT

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile-onset systemic lupus erythematosus (JoSLE) is associated with low bone mass for age and fractures, nevertheless risk factors and predictors of bone involvement are poorly understood in this condition. The aim of this study was to evaluate the risk factors for bone mass loss in patients with JoSLE analyzing clinical and laboratory data and bone microarchitecture parameters.

Methods: This study enrolled a sample of 49 female JoSLE patients, all of them with diagnosis, according to ACR classification criteria (2012 SLICC). All these patients were evaluated at baseline and after 3.5 years of follow-up in relation to: clinical data associated with the disease, lifestyle habits, treatment, laboratory tests including bone turnover markers (N-terminal propeptide of type 1 collagen – P1NP; C-terminal telopeptide of type 1 collagen – CTX), areal bone mineral density (aBMD) by dual X-ray absorptiometry (DXA) at lumbar spine and hip and parameters of bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) at distal tibia and radius. Vertebral fractures were analyzed using DXA (VFA, Genant’s method). aBMD changes above the least significant change were considered significant. Based on the difference between final and baseline aBMD value, the patients were divided into 3 groups: aBMD gain (BG), aBMD loss (BL) and aBMD no change (NC).

Results: The mean age of patients was 18.7 ± 3.3 years and the mean disease duration was 6.0 ± 3.9 years. Sixty-one percent of patients presented aBMD gain, 18.4% aBMD loss and 22.4% remained stable over this period of follow-up. Comparing the BL group with the BG group, there was a higher frequency of alcohol consumption (33.3 vs. 0%, p = 0.009), a higher frequency of inadequate calcium intake (66.7 vs. 26.7%, p = 0.047) and lower serum levels of baseline P1NP (52.42 ± 33.56 vs. 119.72 ± 85.78 ng/mL, p = 0.036) in the former group. Moreover, a worse evolution of HR-pQCT bone parameters: trabecular volumetric density at tibia (-16.36 ± 15.71 vs. -1.55 ± 10.83 mg/cm³, p = 0.003) and cortical thickness at tibia (-0.025 ± 0.09 vs. 0.054 ± 0.07 mm, p = 0.009) was observed in the BL group. In addition, a higher frequency of renal activity was observed when the BL and NC groups were associated and compared to the BG group (52.6 vs. 23.3%, p = 0.036). No significant differences were observed regarding other clinical, laboratorial and microarchitecture bone parameters and treatment.

Conclusion: This is the first longitudinal study in the literature that analyzed the risk factors of bone mass loss in JoSLE patients. The authors emphasize the importance of evaluating not only renal disease activity, but also lifestyle habits, mainly alcoholism and calcium intake in these young women. Furthermore, this study suggests that trabecular and cortical bone compartments were deteriorated in this disease and that low serum levels of P1NP may be a predictor of bone involvement in JoSLE.


Disclosure: L. A. Sousa, None; J. Paupitz, None; N. E. Aikawa, None; L. Takayama, None; V. F. Caparbo, None; R. M. R. Pereira, None.

To cite this abstract in AMA style:

Sousa LA, Paupitz J, Aikawa NE, Takayama L, Caparbo VF, Pereira RMR. Risk Factors for Bone Loss in Juvenile-Onset Systemic Lupus Erythematosus: A Prospective Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/risk-factors-for-bone-loss-in-juvenile-onset-systemic-lupus-erythematosus-a-prospective-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-bone-loss-in-juvenile-onset-systemic-lupus-erythematosus-a-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology